Aging progression suppressing agent, and food or beverage product comprising the same

Collagen peptide mixtures containing peptides that promote type 17 collagen or glutathione synthase gene expression address hair loss and depigmentation, offering effective antioxidant benefits.

JP2024167913APending Publication Date: 2024-12-04NITTA GELATIN INC

Patent Information

Application Number
JP2024144388
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2019-07-25
Filing Date
2024-08-26
Publication Date
2024-12-04

AI Technical Summary

Technical Problem

Existing collagen peptide mixtures do not effectively suppress hair loss and depigmentation, and there is no reported involvement in glutathione synthesis promotion.

Method used

Incorporating peptides that promote the gene expression of type 17 collagen or glutathione synthase, such as Gly-Pro and Glu-Hyp-Gly, into collagen peptide mixtures to enhance antioxidant effects and inhibit aging.

Benefits of technology

The peptides effectively suppress hair loss and depigmentation by promoting gene expression, thereby enhancing antioxidant effects and reducing oxidative stress.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024167913000001
    Figure 2024167913000001
  • Figure 2024167913000002
    Figure 2024167913000002
  • Figure 2024167913000003
    Figure 2024167913000003
Patent Text Reader

Abstract

To provide an aging progression suppressing agent that produces a suppressive effect on hair loss and depigmentation in the hair of head, or an antioxidant action enhancing effect.SOLUTION: An aging progression suppressing agent comprises both or one of the peptides of Gly-Pro and Glu-Hyp-Gly, a salt thereof, or a chemically modified product thereof.SELECTED DRAWING: None
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to an agent for inhibiting the progression of aging, and to a food or drink containing the same. [Background technology]

[0002] One of the causes of aging is oxidative stress caused by reactive oxygen species, peroxides, etc. on various cells. For example, Non-Patent Document 1 below reports that accumulation of the reactive oxygen species or peroxides in cells that constitute hair follicles leads to graying of hair (hereinafter also referred to as "demipigmentation"). Furthermore, Non-Patent Documents 2 and 3 below report that hair loss and depigmentation associated with aging are promoted by a decrease in type XVII collagen. JP 2009-161509 A (Patent Document 1) discloses that type XVII collagen has the function of suppressing hair loss and depigmentation. [Prior art documents] [Patent documents]

[0003] [Patent Document 1] JP 2009-161509 A [Non-patent literature]

[0004] [Non-Patent Document 1] JM Wood et al., FASEB J, 2009, Vol 23, No.7, pp.2065-75 [Non-Patent Document 2] Matsumura H et al., Science, 2016, Vol 351,pp.575, add4395-1,2 [Non-Patent Document 3] Tanimura S et al., Cell Stem Cell, 2011, Vol 8, pp.177-87 Summary of the Invention [Problem to be solved by the invention]

[0005] On the other hand, a collagen peptide mixture obtained by hydrolyzing collagen or gelatin with a known proteolytic enzyme is known. It has been reported that this collagen peptide mixture has various physiological activities in joints, bones, cartilage, skin, etc. in the body. However, it has not been reported that the collagen peptide mixture has the effect of suppressing hair loss and depigmentation of hair. In addition, glutathione is known as a peptide that exhibits a so-called antioxidant effect of removing active oxygen species and peroxides from the body, but there has been no report that the collagen peptide mixture is involved in the synthesis of this glutathione. For this reason, research is being actively conducted to explore the new physiological activities of the collagen peptide mixture and the collagen-derived peptides contained therein, such as the effect of suppressing the progression of aging, specifically, the effect of suppressing hair loss and depigmentation in the above-mentioned hair, and the effect of promoting the synthesis of glutathione.

[0006] In view of the above circumstances, the present invention aims to provide an agent for inhibiting the progression of aging, which contains a peptide or the like that has at least one of the effects of promoting gene expression of type XVII collagen or gene expression of glutathione synthetase, thereby making it possible to obtain the effect of inhibiting hair loss and depigmentation, or the effect of enhancing antioxidant activity, and a food or beverage containing the same. [Means for solving the problem]

[0007] In searching for new physiological activities of collagen peptide mixtures, the present inventors discovered that a certain peptide contained in the collagen peptide mixture has at least one of the following effects: promoting the gene expression of collagen XVII or promoting the gene expression of glutathione synthetase. Based on this discovery, they arrived at an aging progression inhibitor that can obtain the effect of suppressing hair loss and depigmentation or the effect of enhancing antioxidant activity by containing the above peptide, and thus completed the present invention.

[0008] Specifically, the present invention is as follows. The agent for inhibiting the progression of aging according to the present invention contains both or either one of the peptides Gly-Pro and Glu-Hyp-Gly, or a salt thereof, or a chemically modified form thereof.

[0009] Preferably, the peptide is derived from collagen. The aging progression inhibitor is preferably a collagen peptide mixture containing the peptide.

[0010] The collagen peptide mixture preferably has a weight average molecular weight of 100 Da or more and 5000 Da or less.

[0011] The aging progression inhibitor is preferably a promoter for promoting the expression of the gene for type 17 collagen or a promoter for promoting the expression of the gene for glutathione synthetase.

[0012] The food and drink according to the present invention contains the above-mentioned agent for inhibiting the progression of aging. Effect of the Invention

[0013] According to the present invention, it is possible to provide an agent for inhibiting the progression of aging, which is capable of suppressing hair loss and depigmentation, or of enhancing antioxidant activity, and a food or beverage containing the same. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0014] Hereinafter, the embodiment of the present invention will be described in more detail. In this specification, the expression in the form of "A to B" means the upper and lower limits of a range (i.e., A or more and B or less), and when no unit is described for A and only a unit is described for B, the unit of A and the unit of B are the same.

[0015] [Aging inhibitor] The aging progression inhibitor of the present invention contains both or either of Gly-Pro and Glu-Hyp-Gly peptides, or their salts, or their chemically modified forms. The aging progression inhibitor having such characteristics can exhibit at least one of the effects of promoting the gene expression of type XVII collagen or the gene expression of glutathione synthetase, thereby making it possible to obtain the effect of suppressing hair loss and depigmentation, or the effect of enhancing the antioxidant effect.

[0016] [Gly-Pro and / or Glu-Hyp-Gly peptides, or salts thereof, or chemically modified forms thereof] As described above, the aging progression inhibitor contains both or either of the peptides Gly-Pro and Glu-Hyp-Gly, or salts thereof, or chemically modified forms thereof. In this specification, the "amino acids" constituting the above peptides are expressed by three-letter abbreviations unless otherwise specified. Furthermore, "amino acids" refer to L-type amino acids unless otherwise specified. Furthermore, in this specification, "peptide" means, for example, a peptide (dipeptide) in which glycine and proline are arranged from the N-terminus toward the C-terminus in the order "Gly-Pro", and a peptide (tripeptide) in which glutamic acid, hydroxyproline, and glycine are arranged from the N-terminus toward the C-terminus in the order "Glu-Hyp-Gly". This also applies to peptides other than "Gly-Pro" and "Glu-Hyp-Gly".

[0017] The aging progression inhibitor preferably contains both Gly-Pro and Glu-Hyp-Gly peptides, or a salt thereof, or a chemically modified form thereof, in which case the aging progression inhibitor can more significantly exhibit the effect of promoting the gene expression of type XVII collagen or the gene expression of glutathione synthetase.

[0018] The "salts" of the above peptides are formed, for example, as inorganic acid salts such as hydrochloride, sulfate, phosphate, etc. of the above peptides; organic acid salts such as methanesulfonate, benzenesulfonate, succinate, oxalate, etc.; inorganic base salts such as sodium salt, potassium salt, calcium salt, etc.; and organic base salts such as triethylammonium salt, etc.

[0019] The "chemically modified" peptide means a compound in which the free functional group of the amino acid residue, which is a constituent unit, is chemically modified. Chemical modification can be performed, for example, on the hydroxyl group of hydroxyproline, the amino group of the N-terminal (amino terminal) amino acid, and the carboxyl group of the C-terminal (carboxyl terminal) amino acid. As the specific means of chemical modification and the treatment conditions thereof, conventionally known chemical modification techniques for amino acids and peptides are applied. Such chemical modification can provide the above-mentioned chemically modified amino acids and peptides with the effects of improving solubility in weakly acidic to neutral conditions, improving compatibility with other active ingredients, and the like.

[0020] For example, for a tripeptide Glu-Hyp-Gly, the hydroxyl group in hydroxyproline can be chemically modified by O-acetylation. This O-acetylation can be carried out, for example, by the action of acetic anhydride in an aqueous or non-aqueous solvent. The carboxyl group in glycine can be chemically modified by esterification, amidation, etc. The esterification can be carried out by suspending the peptide in methanol and then bubbling dry hydrogen chloride gas through the suspension. The amidation can be carried out by the action of carbodiimide, etc. on the peptide.

[0021] Furthermore, a free amino group in a peptide can be chemically modified by methylation, and a free hydroxyl group in a peptide can be chemically modified by at least one of phosphorylation and sulfation.

[0022] The peptide is preferably derived from collagen. In this case, the collagen as a raw material can be obtained by carrying out a conventionally known degreasing or demineralizing treatment, extraction treatment, etc. on the hide, skin, bone, cartilage, tendon, etc. of animals such as cows, pigs, sheep, chickens, ostriches, etc., or the bones, skin, scales, etc. of fish. Furthermore, gelatin can also be used as a raw material for the peptide. Gelatin can be obtained by treating the collagen obtained as described above with a conventionally known method such as hot water extraction. Commercially available collagen and gelatin can also be used as raw materials.

[0023] The peptide can be obtained by hydrolyzing both or either of the collagen and gelatin with a combination of two or more types of endo-type proteases and exo-type proteases. The peptide is obtained as a collagen peptide mixture mixed with other collagen peptides by the hydrolysis, and this collagen peptide mixture itself and a partially purified mixture thereof can be used as the aging progression inhibitor of the present invention. That is, the aging progression inhibitor is preferably a collagen peptide mixture. Furthermore, by further purifying the collagen peptide mixture, a purified product containing the above-mentioned peptide can be obtained with high purity. When the peptide is derived from collagen, it is preferable to obtain it by using a method of treating collagen or gelatin with enzymes in two stages, which will be described later.

[0024] Furthermore, the collagen peptide mixture preferably has a weight-average molecular weight of 100 Da or more and 5000 Da or less. The weight-average molecular weight of the collagen peptide mixture is more preferably 120 Da or more and 3500 Da or less, and even more preferably 150 Da or more and 3000 Da or less. When the weight-average molecular weight of the collagen peptide mixture is within the above-mentioned range, the aging progression inhibitor can more fully obtain the effect of promoting the gene expression of collagen XVII or the gene expression of glutathione synthetase. When the weight-average molecular weight exceeds 5000 Da, the aging progression inhibitor may not have the above-mentioned effect.

[0025] The weight-average molecular weight of the collagen peptide mixture can be determined by carrying out size exclusion chromatography (SEC) under the following measurement conditions. Equipment: High performance liquid chromatography (HPLC) (Tosoh Corporation) Column: TSKgel® G2000SW XL Column temperature: 40℃ Column size: 7.8mm I.D. x 30cm, 5μm Eluent: 45% by mass acetonitrile (containing 0.1% by mass trifluoroacetic acid) Flow rate: 1.0mL / min Injection volume: 10μL Detection: UV214nm Molecular weight markers: The following five types are used Cytochrom C Mw:12000 Aprotinin Mw:6500 Bacitracin Mw:1450 Gly-Gly-Tyr-Arg Mw: 451 Gly-Gly-Gly Mw: 189.

[0026] Specifically, a sample containing about 0.2 g of the above-mentioned collagen peptide mixture is added to about 100 ml of distilled water, stirred, and then filtered through a 0.2 μm filter to prepare a sample (subject) for measuring the weight-average molecular weight. The weight-average molecular weight of the collagen peptide mixture can be determined by subjecting the subject to the above-mentioned size exclusion chromatography.

[0027] [Method of producing aging inhibitor] The peptide contained in the aging progression inhibitor can be obtained by a conventionally known method. For example, the peptide can be obtained by purchasing commercially available amino acids. The peptide can also be obtained by hydrolyzing collagen or gelatin.

[0028] The above peptides (Gly-Pro and / or Glu-Hyp-Gly) can be obtained by using a conventionally known liquid-phase or solid-phase peptide synthesis method, or a method of hydrolyzing collagen or gelatin. From the viewpoint of efficiency, the above peptides are preferably produced by using a chemical synthesis method using amino acids described below, or a method of enzymatically treating collagen or gelatin in two stages described below. Furthermore, instead of the method of enzymatically treating collagen or gelatin in two stages, the above peptides can also be produced by a method of enzymatically treating collagen or gelatin only with a secondary enzyme without the primary enzyme, or a method of enzymatically treating the primary and secondary enzymes simultaneously. Hereinafter, focusing on "Glu-Hyp-Gly" among the peptides contained in the aging progression inhibitor, a method of producing this will be described as an example of a method of producing a peptide contained in the aging progression inhibitor.

[0029] <Chemical synthesis method> The above peptide can be obtained by using a general peptide synthesis method. As the peptide synthesis method, a solid phase synthesis method and a liquid phase synthesis method are known. As the solid phase synthesis method, the Fmoc method and the Boc method are known. The above peptide can be obtained by using either the Fmoc method or the Boc method. As a solid phase peptide synthesis method, a synthesis method of a tripeptide represented by Glu-Hyp-Gly can be performed as follows.

[0030] First, polystyrene polymer gel beads with a diameter of about 0.1 mm whose surface is modified with amino groups are prepared as a solid phase. Diisopropylcarbodiimide is separately prepared as a condensation agent. Next, the amino group of glycine, which is the amino acid at the C-terminus (carboxyl terminus) side in the above amino acid sequence, is protected with an Fmoc (fluorenyl-methoxy-carbonyl) group, and the carboxyl group of the glycine is peptide-bonded to the amino group of the solid phase by a dehydration reaction using the above condensation agent. Furthermore, the solid phase is washed with a solvent to remove the remaining condensation agent and amino acid, and then the protecting group of the amino group of glycine peptide-bonded to the solid phase is removed (deprotected).

[0031] Next, hydroxyproline with its amino group protected by an Fmoc group is prepared, and the carboxyl group of this hydroxyproline is peptide-bonded to the deprotected amino group of the glycine by using the condensing agent. Thereafter, the amino group of the hydroxyproline is deprotected in the same manner, glutamic acid is prepared with an Fmoc group, and the reaction of peptide-bonding this glutamic acid and the hydroxyproline is carried out, thereby synthesizing a tripeptide represented by Glu-Hyp-Gly on the solid phase. Finally, the amino group of the glutamic acid is deprotected, and the tripeptide is digested with trifluoroacetic acid to separate it from the solid phase, thereby producing the tripeptide.

[0032] <Production method using collagen or gelatin> Furthermore, a method for producing a tripeptide represented by Glu-Hyp-Gly by subjecting collagen or gelatin to a two-step enzymatic treatment can be carried out as follows.

[0033] Here, "two-stage enzymatic treatment" of collagen or gelatin means the following. That is, after performing a first enzymatic treatment by a conventionally known method for cleaving the peptide bonds of collagen or gelatin, a second enzymatic treatment is performed by an enzyme having aminopeptidase N activity, an enzyme having both aminopeptidase N activity and prolyl tripeptidyl aminopeptidase activity, or a combination of an enzyme having aminopeptidase N activity and an enzyme having prolyl tripeptidyl aminopeptidase activity. By performing the first enzymatic treatment, a collagen peptide mixture precursor can be obtained. Furthermore, by performing the second enzymatic treatment, a collagen peptide mixture containing the Glu-Hyp-Gly can be obtained from the collagen peptide mixture precursor. The method of performing two-stage enzymatic treatment of collagen or gelatin will be described in more detail below.

[0034] (First enzyme treatment) The enzyme used in the first enzyme treatment should not be particularly limited as long as it is an enzyme capable of cleaving the peptide bond of collagen or gelatin, and any proteolytic enzyme can be used. Specifically, collagenase, thiol protease, serine protease, acid protease, alkaline protease, metal protease, etc. can be mentioned, and one selected from these groups may be used alone, or two or more may be used in combination. As the thiol protease, plant-derived chymopapain, papain, bromelain, ficin, animal-derived cathepsin, calcium-dependent protease, etc. can be used. As the serine protease, trypsin, cathepsin D, etc. can be used. As the acid protease, pepsin, chymotrypsin, etc. can be used. As the enzyme used in the first enzyme treatment, when considering that the aging progression inhibitor according to the present invention is used in medicine, specified health food, etc., it is preferable to use an enzyme other than the enzyme derived from a pathogenic microorganism.

[0035] The amount of enzyme in the first enzyme treatment is preferably 0.1 to 5 parts by mass of the enzyme described above per 100 parts by mass of collagen or gelatin. The treatment temperature in the first enzyme treatment is preferably 30 to 65°C, and the treatment time is preferably 10 minutes to 72 hours. The weight-average molecular weight of the collagen peptide mixture precursor obtained by the first enzyme treatment is preferably 500 to 20,000 Da, more preferably 500 to 10,000 Da, and even more preferably 500 to 8,000 Da. If the weight-average molecular weight is within the above range, it can be said that peptides with appropriate molecular weights are sufficiently produced. After the first enzyme treatment, the enzyme can be inactivated as necessary. In this case, the inactivation temperature is preferably 70 to 100°C. The weight-average molecular weight of the collagen peptide mixture precursor can be determined by the method using SEC described above.

[0036] (Secondary enzyme treatment) Examples of the enzyme used in the secondary enzyme treatment include an enzyme having aminopeptidase N activity, an enzyme having both aminopeptidase N activity and prolyl tripeptidyl aminopeptidase activity, or a combination of an enzyme having aminopeptidase N activity and an enzyme having prolyl tripeptidyl aminopeptidase activity. Here, in the present specification, the term "enzyme having aminopeptidase N activity" refers to a peptidase that has the function of releasing an amino acid from the N-terminus of a peptide chain, and acts when an amino acid other than proline or hydroxyproline is present at the second position from the N-terminus. In the present specification, the term "enzyme having prolyl tripeptidyl aminopeptidase activity" refers to a peptidase that releases only the three amino acid residues at the N-terminus from a peptide in which the third position from the N-terminus is proline or hydroxyproline. When considering that the aging progression inhibitor according to the present invention is used in medicines, foods for specified health uses, etc., it is preferable to use enzymes other than those derived from pathogenic microorganisms as the enzyme used in the secondary enzyme treatment.

[0037] Examples of the enzymes having aminopeptidase N activity include aminopeptidase N (EC3.4.11.2.; T. Yoshimoto et al., Agric. Biol. Chem., 52:217-225(1988)). Examples of the enzymes having aminopeptidase N activity derived from the genus Aspergillus include. Examples of the enzymes having prolyl tripeptidyl aminopeptidase activity include prolyl tripeptidyl aminopeptidase (EC3.4.14.; A. Banbula et al., J. Biol. Chem., 274:9246-9252(1999)).

[0038] By carrying out the secondary enzyme treatment, a collagen peptide mixture containing peptides not contained in the collagen peptide mixture precursor can be obtained. Specifically, a collagen peptide mixture containing the Glu-Hyp-Gly can be obtained.

[0039] The amount of enzyme in the secondary enzyme treatment is preferably 0.01 to 5 parts by mass of the enzyme per 100 parts by mass of the collagen peptide mixture precursor. The treatment temperature in the secondary enzyme treatment is preferably 30 to 65°C, and the treatment time is preferably 10 minutes to 72 hours. The weight-average molecular weight of the collagen peptide mixture obtained by the secondary enzyme treatment is preferably 100 to 5000 Da, more preferably 120 to 3500 Da, and even more preferably 150 to 3000 Da. The weight-average molecular weight of the collagen peptide mixture can also be determined by the method using the SEC described above.

[0040] The secondary enzyme treatment is carried out mainly for the purpose of producing the above-mentioned tripeptide of Glu-Hyp-Gly. For this reason, it is preferable to adjust the amount of enzyme, treatment temperature, treatment time and pH in the secondary enzyme treatment so that the peptides contained in the collagen peptide mixture precursor are not excessively hydrolyzed. This makes it preferable to make the collagen peptide mixture within the above-mentioned range of weight average molecular weight. After the secondary enzyme treatment, it is necessary to inactivate the enzyme. In this case, the inactivation temperature is preferably, for example, 70 to 100°C. Furthermore, it is preferable to perform a sterilization treatment at 120°C for several seconds or more. It is also possible to apply heat of 200°C or more to this and spray dry it.

[0041] In the secondary enzyme treatment, in addition to the above-mentioned enzyme having aminopeptidase N activity and enzyme having prolyl tripeptidyl aminopeptidase activity, enzymes having different activities can be used, and two or more enzymes having different activities can be used in combination. This makes it possible to decompose and remove by-products. In this case, the enzyme to be used is preferably selected appropriately depending on the type of collagen used as the raw material and the type of enzyme used in the primary enzyme treatment. Examples of the above-mentioned different activities include dipeptidase activities such as prolidase activity and hydroxyprolidase activity. This makes it possible to decompose and remove by-products such as dipeptides.

[0042] Furthermore, aminopeptidase N activity is basically an activity that releases amino acids one by one on the N-terminal side. Therefore, when the collagen peptide mixture precursor obtained by the first enzyme treatment contains peptides with extremely large molecular weights, the processing time will be significantly extended if the second enzyme treatment is performed only with an enzyme having aminopeptidase N activity. To deal with such cases, for example, prolyl oligopeptidase, an endopeptidase that has the activity of hydrolyzing the carboxyl group side of proline (prolidase activity), can be used in the second enzyme treatment. This allows the second enzyme treatment to be performed efficiently.

[0043] In the method of treating collagen or gelatin with an enzyme in two stages, a peptide with a relatively large molecular weight can be produced by the first enzyme treatment. This peptide can have an amino acid sequence represented by, for example, [X1-Gly-X2-Glu-Hyp-Gly] (X1 and X2 ≠ Hyp). In the subsequent second enzyme treatment, an enzyme having aminopeptidase N activity acts on the peptide represented by [X1-Gly-X2-Glu-Hyp-Gly], and X1 at the N-terminus is liberated to obtain a peptide having an amino acid sequence represented by [Gly-X2-Glu-Hyp-Gly]. Next, an enzyme having aminopeptidase N activity acts twice on the peptide represented by [Gly-X2-Glu-Hyp-Gly], and glycine and X2 are liberated to obtain a peptide represented by [Glu-Hyp-Gly].

[0044] (Purification of collagen peptide mixture) By carrying out the above-mentioned two-stage enzyme treatment, a collagen peptide mixture containing Glu-Hyp-Gly can be produced. Since the above-mentioned collagen peptide mixture also contains peptides other than the tripeptide represented by Glu-Hyp-Gly, it is preferable to purify it as necessary. In this case, the purification method can be a conventionally known method, for example, various liquid chromatography such as ultrafiltration, size exclusion chromatography, ion exchange chromatography, reverse phase chromatography, and affinity chromatography can be used.

[0045] Specifically, the collagen peptide mixture can be purified by the following procedure: About 2 g / 10 mL of the collagen peptide mixture is loaded onto an ion exchange column (e.g., trade name: "Toyopearl (registered trademark) DEAE-650", manufactured by Tosoh Corporation), and the first void volume fraction eluted with distilled water is collected. Next, the first void volume fraction is loaded onto a column having an ion exchange group opposite to that of the ion exchange column (e.g., trade name: "Toyopearl (registered trademark) SP-650", manufactured by Tosoh Corporation), and the second void volume fraction eluted with distilled water is collected.

[0046] Next, the second void volume fraction is loaded onto a gel filtration column (e.g., Sephadex LH-20, manufactured by GE Healthcare Japan, Inc.) and eluted with 30% by mass of methanol aqueous solution to recover a fraction containing the tripeptide Glu-Hyp-Gly. Finally, this fraction is fractionated with a linear concentration gradient of 32% or less acetonitrile aqueous solution containing 0.1% by mass of trifluoroacetic acid using a high performance liquid chromatography (HPLC) equipped with a reverse phase column (e.g., μBondasphere 5μC18 300Å column, manufactured by Waters Corporation), to obtain Glu-Hyp-Gly in high purity.

[0047] [Gene expression promoter for type XVII collagen or gene expression promoter for glutathione synthesis enzyme] The aging progression inhibitor of the present invention is preferably a gene expression promoter for type 17 collagen or a gene expression promoter for glutathione synthesis enzyme. As described above, the aging progression inhibitor contains both or either of Gly-Pro and Glu-Hyp-Gly peptides, or a salt thereof, or a chemically modified form thereof. This can promote the gene expression of type 17 collagen. Therefore, the aging progression inhibitor can promote the gene expression of type 17 collagen as a gene expression promoter for type 17 collagen, thereby suppressing hair loss and depigmentation. Since the gene expression promoter for type 17 collagen promotes the gene expression of type 17 collagen, it can be expected to have the effect of suppressing the progression of age-related thinning hair, hair loss, and gray hair, as well as the effect of promoting beautiful skin.

[0048] Furthermore, the aging progression inhibitor contains the above peptide, or its salt, or its chemically modified form, and therefore can promote the expression of glutathione synthesis enzyme gene.Therefore, the aging progression inhibitor promotes the expression of glutathione synthesis enzyme gene as a glutathione synthesis enzyme gene expression promoter, and can remove active oxygen species, peroxides, etc. from the body.Since the glutathione synthesis enzyme gene expression promoter can remove active oxygen species, peroxides, etc. from the body, it can be expected to achieve effects such as whitening based on the inhibition of pigmentation caused by inflammation, beautiful skin based on the inhibition of eczema, promotion of healing of corneal damage, improvement of liver function, and improvement of Parkinson's disease.

[0049] The aging inhibitor can be administered orally or parenterally in various forms. When administered orally, the form can be, for example, a tablet, granule, capsule, powder, liquid, suspension, emulsion, etc. Furthermore, the aging inhibitor in the above-mentioned form can be mixed with food and drink. The aging inhibitor includes the above-mentioned peptides, which are rapidly absorbed in the intestinal tract and can be taken by oral administration.

[0050] When the aging progression inhibitor is administered parenterally, it can be in the form of an external preparation such as an ointment, cream, or lotion, or a transdermal preparation. It can also be in the form of a liquid or liniment for direct application to the scalp. When the aging progression inhibitor is in the form of a liniment, the concentration of the peptide or the like contained in the liniment is preferably 0.001 to 5% by mass.

[0051] The dosage of the aging progression inhibitor varies depending on the age, sex, weight, sensitivity difference, administration method, administration interval, type of preparation, etc. of the subject. When the aging progression inhibitor is orally administered, the dosage is preferably 0.0001 to 2500 mg / kg per day for an adult, and more preferably 0.0001 to 500 mg / kg per day. When the aging progression inhibitor is in the form of a tablet, for example, it can be a tablet containing the aging progression inhibitor at 0.001 to 80% by mass per tablet, and when it is in the form of a powder, it can be a powder containing the aging progression inhibitor at 0.001 to 100% by mass. The dosage can be appropriately determined by referring to the dosage when administered parenterally or by administering in other forms of preparation. The aging progression inhibitor can be administered once or in several divided doses per day, or once every one to several days.

[0052] The aging progress inhibitor may contain other active ingredients, carriers for formulation, etc., as appropriate, within the scope that does not adversely affect the effects of the present invention. Other active ingredients include inulin, caffeic acid, quinic acid and their derivatives, extracts from marjoram, various herbal medicines such as kinbukan, polygala gracilis, white eye grass, and false hawk claw, royal jelly, extracts from echinacea, extracts from acai, and extracts from cupuacu. Furthermore, pharmaceutically acceptable carriers used in formulation into pharmaceutical preparations include diluents, binders (syrup, gum arabic, gelatin, sorbitol, tragacanth, polyvinylpyrrolidone), excipients (lactose, sucrose, corn starch, potassium phosphate, sorbitol, glycine), lubricants (magnesium stearate, talc, polyethylene glycol, silica), disintegrants (potato starch), and wetting agents (sodium lauryl sulfate).

[0053] [Use invention] The aging progression inhibitor according to the present invention contains both or either one of the peptides Gly-Pro and Glu-Hyp-Gly, or a salt thereof, or a chemically modified form thereof, as described above. The aging progression inhibitor can exhibit at least one of the following attributes of the peptide: an action of promoting gene expression of type XVII collagen, or an action of promoting gene expression of glutathione synthetase. In other words, the present invention can be said to be a peptide, or a salt thereof, or a chemically modified form thereof, which has been newly found to be used for suppressing the progression of aging based on the above attributes.

[0054] [Food and beverages] The food and drink according to the present invention contains the aging inhibitor. For example, the peptide preferably contained in the aging inhibitor is rapidly absorbed in the intestinal tract as described above, and can be taken by oral administration. Therefore, the present invention can be taken by mixing the aging inhibitor with food or drink as a food and drink containing the aging inhibitor. Furthermore, the aging inhibitor according to the present invention can be used as a specified health food or a functional food. The concentration of the aging inhibitor contained in the food and drink is preferably 0.001 to 100% by mass. EXAMPLES

[0055] The present invention will be described in more detail below with reference to examples, but the present invention is not limited to these.

[0056] [Example 1] [Sample preparation] <Preparation of peptides and collagen peptide mixture> The peptides and collagen peptide mixtures shown in Tables 1 to 4 below were prepared by the methods described above or by purchasing them from the manufacturers described below. The peptides and collagen peptide mixtures described above serve as samples for evaluating whether they affect the messenger RNA amount (mRNA amount) of collagen XVII gene and the mRNA amount of glutathione synthetase gene in epidermal cells described below.

[0057] Here, the peptides shown in Tables 1 and 2 are abbreviated to represent the constituent amino acids with one letter. In Table 1, "EO" is a dipeptide represented by glutamic acid-hydroxyproline (manufactured by PH Japan Co., Ltd.). "GP" is a dipeptide represented by glycine-proline (trade name: "G-3015", manufactured by BACHEM). "EOG" is a tripeptide represented by glutamic acid-hydroxyproline-glycine (manufactured by PH Japan Co., Ltd.).

[0058] Furthermore, collagen peptide mixture A shown in Table 3 (product name: "Colapep PU", manufactured by Nitta Gelatin Co., Ltd., weight average molecular weight (Mw): approximately 630 Da) contained the following amounts of "EOG" and "GP" in quantitative analysis by LC-MS / MS performed under the conditions described below. Glu-Hyp-Gly: 4ppm, Gly-Pro: 2379ppm, total: 2383ppm.

[0059] Next, collagen peptide mixture B shown in Table 4 (product name: "TYPE-S", manufactured by Nitta Gelatin Co., Ltd., weight average molecular weight (Mw): approximately 750 Da) contained the following amounts of "EOG" and "GP" in quantitative analysis by LC-MS / MS performed under the conditions described below. Glu-Hyp-Gly: 9ppm, Gly-Pro: 1159ppm, total: 1168ppm.

[0060] Collagen peptide mixture C shown in Table 4 is a collagen peptide mixture (weight average molecular weight (Mw): approximately 450 Da) being developed by Nitta Gelatin Co., Ltd., and contained the following amounts of "EOG" and "GP" in quantitative analysis by LC-MS / MS performed under the conditions described below. Glu-Hyp-Gly: 24ppm, Gly-Pro: 26387ppm, total: 26411ppm.

[0061] Quantitative analysis by LC-MS / MS was carried out under the following conditions. HPLC equipment: "ACQUITY UPLC H-Class Bio", Waters Corporation) Column: Hypersil GOLD PFP 2.1 x 150 mm, 5 μm (Thermo Fisher Scientific, Inc.) Column temperature: 40°C (linear gradient) Mobile phase: (A) Aqueous solution containing 0.2% formic acid and 2 mM ammonium acetate (B) 100% methanol (Gradient settings) Time (min) Flow rate (μL / min) Mass % of mobile phase (A) Initials 200 98 3.50 200 98 3.51 400 5 7.00 400 5 7.10 200 98 17.00 200 98 Injection volume: 0.5 μl.

[0062] MS / MS device: "Xevo TQ-XS", manufactured by Waters Corporation Ionization method: Positive ESI Capacitor (kV):1 Desolvation temperature(℃):500 Source temperature(℃):150 MRM conditions: Peptide (abbreviation) precursor ion (m / z) product ion (m / z) Gly-Pro(GP) 173 116 Glu-Hyp-Gly(EOG) 318 225.

[0063] <Preparation of epidermal cells> First, human normal epidermal keratinocytes NHEK (NB) (Kuraray Industries, Inc.) were obtained as epidermal cells. The above cells were placed in a required number of commercially available φ60 mm petri dishes at 1.25 × 10 4 pieces (0.25×10 4 The cells were seeded with 5 mL of cell dispersion having a concentration of 1000 cells / mL and cultured in serum-free medium (product name: "HuMedia KG-2", manufactured by Kuraray Industries, Inc.) for 2 days. After confirming that the cells were subconfluent in the dish, the medium in the dish was replaced with basal medium (product name: "HuMedia KB-2", manufactured by Kuraray Industries, Inc.). In this way, epidermal cells were prepared for evaluating the amount of mRNA of type XVII collagen gene and the amount of mRNA of glutathione synthetase gene.

[0064] <Gene expression test> The above peptides or collagen peptide mixtures were added to the basal medium in each petri dish at the concentrations shown in Tables 1 to 4, and the samples were cultured at 37°C for 72 hours in an atmosphere with a carbon dioxide concentration of 5% by volume to prepare samples for gene expression testing. In addition, a control sample (hereinafter also referred to as "Blank") was prepared by adding only ion-exchanged water to the basal medium in the petri dish. This control sample was also cultured at 37°C for 72 hours in an atmosphere with a carbon dioxide concentration of 5% by volume.

[0065] Next, total RNA was extracted from the epidermal cells in the petri dish using an RNA extraction kit (trade name: "TRIzol (registered trademark) Reagent", manufactured by Life Technologies Japan, Inc.) according to the protocol attached to the kit, thereby obtaining an extract containing total RNA for each sample. Subsequently, reverse transcription was performed on the RNA in the extract using a cDNA preparation kit (trade name (product number): "High Capacity RNA-to-cDNA Kit (4387406)", manufactured by Life Technologies Japan, Inc.) according to the protocol attached to the kit, thereby obtaining cDNA from the RNA in the extract. Furthermore, real-time (RT)-PCR was performed on the cDNA using a DNA amplification device (trade name: "Step One Plus (TM) Real-time PCR System", manufactured by Applied Biosystems).

[0066] In the above RT-PCR, the mRNA amounts of collagen XVII (Life Technologies Japan, primer: Hs009900361_ml) and glutathione synthetase (GSS, Life Technologies Japan, primer: Hs01547656_ml) were measured as target genes. GAPDH was selected as the internal standard (correction gene). The calibration curve method was used to calculate the mRNA amount. The primers and probes used in the above RT-PCR were those included in the reagent kit (product name: "TaqMan (registered trademark) Gene Expression Assays", Applied Biosystems).

[0067] The data obtained from the above RT-PCR was analyzed as follows. First, the amount of mRNA (gene expression level) of the two target genes (type XVII collagen and glutathione synthetase) was calculated for each sample and the control sample. Next, the amount of mRNA of the two target genes was corrected with the amount of GAPDH mRNA used as a correction gene to obtain a correction value for each sample and the control sample. Specifically, the amount of mRNA of the two target genes was divided by the amount of GAPDH mRNA to obtain a value (relative value).

[0068] Next, the ratio of the corrected value obtained for each sample to the corrected value of the control sample was calculated (gene expression increase rate (%)), assuming the corrected value of the control sample to be 100. In this way, the effect of adding the peptide and collagen peptide mixture on the amount of mRNA of type XVII collagen gene and the amount of mRNA of glutathione synthetase gene (presence or absence of gene expression promoting effect) in the epidermal cells was evaluated.

[0069] Furthermore, the gene expression increase rate (%) was statistically processed to evaluate the significance of the gene expression promoting effect of the type 17 collagen gene and glutathione synthetase gene in each sample. This significance was evaluated by performing Smirnov-Grubbs (two-sided test) using software (product name: "Excel Statistics (Ver2.1)" manufactured by Social Information Services Co., Ltd.) for statistical processing, and setting the threshold value as the significance level (P value) to 0.01. Then, it was decided to judge by performing Student's t-test. The results are shown in Tables 1 to 4. In Tables 1 to 4, in the samples marked with "++", it was judged that the expression promoting effect of the above genes was significant. In the samples marked with "+", the gene expression increase rate (%) exceeded 100. In the samples marked with "-", it was judged that the expression promoting effect of the above genes was not significant.

[0070] Table 1 shows the rate of increase in gene expression of type 17 collagen gene when each of the peptides "EO", "GP" and "EOG" is added to epidermal cells. Table 2 shows the rate of increase in gene expression of glutathione synthetase gene when each of the peptides "GP" and "EOG" is added to epidermal cells. Table 3 shows the rate of increase in gene expression of type 17 collagen gene when the above-mentioned "collagen peptide mixture A" is added to epidermal cells. Table 4 shows the increase in the rate of increase in gene expression of glutathione synthetase gene when the above-mentioned "collagen peptide mixture B" and "collagen peptide mixture C" are added to epidermal cells.

[0071] [Table 1]

[0072] [Table 2]

[0073] [Table 3]

[0074] [Table 4]

[0075] [Consideration] According to Tables 1 to 4, it can be understood that the samples containing both or either of the peptides Gly-Pro (GP) and Glu-Hyp-Gly (EOG) have at least one of the effects of promoting the gene expression of type XVII collagen or the gene expression of glutathione synthetase. Collagen peptide mixtures A to C containing these peptides also had at least one of the effects of promoting the gene expression of type XVII collagen or the gene expression of glutathione synthetase. On the other hand, the sample containing the peptide represented by Glu-Hyp (EO) did not show a clear effect of promoting the gene expression of type XVII collagen. This suggests that the above-mentioned Gly-Pro and Glu-Hyp-Gly peptides, as well as collagen peptide mixtures containing them, have the effect of suppressing hair loss and depigmentation in hair by promoting the gene expression of type XVII collagen as an agent for suppressing the progression of aging. Furthermore, it has been suggested that the above peptides, as well as collagen peptide mixtures containing them, act as inhibitors of the progression of aging by promoting the gene expression of glutathione synthesis enzyme, thereby promoting the synthesis of glutathione, and thus exerting an antioxidant effect of removing reactive oxygen species, peroxides, etc. from the body.

[0076] [Example 2] [Sample preparation] <Preparation of collagen peptide mixture> Collagen peptide mixture D (product name: "Collagenide", manufactured by Nitta Gelatin Co., Ltd., weight average molecular weight (Mw): about 4000 Da) was prepared as a collagen peptide mixture containing both or either of Gly-Pro (GP) and Glu-Hyp-Gly (EOG) peptides. Collagen peptide mixture D contained a total of 132 ppm of "EOG" and "GP" in quantitative analysis by LC-MS / MS performed under the same conditions as in [Example 1] described above.

[0077] [Study on inhibition of aging progression using human subjects] A total of 95 subjects (2 men, 92 women) in the age group of 10 to 70 years old were given collagen peptide mixture D, and we investigated whether the subjects felt an effect of inhibiting the progression of aging. Specifically, the 95 subjects orally took 4 to 6 g of collagen peptide mixture D per day for 10 to 20 days (average 14 days) without specifying the time of intake. After that, if the subjects felt an effect of inhibiting the progression of aging, we conducted an interview survey (questionnaire survey) to ask about the details of the effect (specific content) along with the area where the effect was felt.

[0078] The results are shown in Tables 5 to 10. Table 5 shows the areas where the inhibitory effect on the progression of aging was felt, and the number of people who felt the inhibitory effect on the progression of aging in those areas (multiple answers allowed). Table 6 shows the specific details of the inhibitory effect on the progression of aging felt in the skin, and the number of people who answered the details (multiple answers allowed). Table 7 shows the specific details of the inhibitory effect on the progression of aging felt in the hair, and the number of people who answered the details (multiple answers allowed). Table 8 shows the specific details of the inhibitory effect on the progression of aging felt in the nails, and the number of people who answered the details (multiple answers allowed). Table 9 shows the specific details of the inhibitory effect on the progression of aging felt in the joints, and the number of people who answered the details (multiple answers allowed). Table 10 shows the specific details of the inhibitory effect on the progression of aging felt in other areas, and the number of people who answered the details (multiple answers allowed).

[0079] [Table 5]

[0080] [Table 6]

[0081] [Table 7]

[0082] [Table 8]

[0083] [Table 9]

[0084] [Table 10]

[0085] [Consideration] According to Tables 5 to 10, it can be seen that collagen peptide mixture D (an agent for inhibiting the progression of aging) containing both or either one of the peptides Gly-Pro (GP) and Glu-Hyp-Gly (EOG) has an effect of inhibiting the progression of aging in the skin, hair, nails, joints and other parts of the body.

[0086] Although the embodiments and examples of the present invention have been described above, it is also intended from the beginning that the configurations of the above-described embodiments and examples may be appropriately combined.

[0087] The embodiments and examples disclosed herein should be considered to be illustrative and not restrictive in all respects. The scope of the present invention is defined by the claims, not the above description, and is intended to include all modifications within the meaning and scope of the claims.

Claims

1. An agent for inhibiting the progression of aging, comprising a peptide selected from the group consisting of Gly-Pro and / or Glu-Hyp-Gly, a salt thereof, and a chemically modified form thereof.

2. The agent for inhibiting the progression of aging according to claim 1 , wherein the peptide is derived from collagen.

3. The aging progression inhibitor according to claim 1 or 2, wherein the aging progression inhibitor is a collagen peptide mixture.

4. The aging progression inhibitor according to claim 3 , wherein the collagen peptide mixture has a weight average molecular weight of 100 Da or more and 5000 Da or less.

5. The aging progression inhibitor according to any one of claims 1 to 4, which is an agent for promoting the expression of a gene for type 17 collagen or an agent for promoting the expression of a gene for glutathione synthetase.

6. A food or drink comprising the aging progression inhibitor according to any one of claims 1 to 5.

Citation Information

Patent Citations

  • Hair loss inhibitor and hair depigmentation inhibitor associated with type xvii collagen

    JP2009161509A

Cited By

  • A type II collagen production promoter in chondrocytes

    JP7894184B1